TITLE

FDA May Alter Rules on Drug Combos

PUB. DATE
September 2010
SOURCE
Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.
ACCESSION #
55600928

 

Related Articles

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

  • FDA panel votes against recommending approval of serelaxin. Swain, Erik // Cardiology Today;Apr2014, Vol. 17 Issue 4, p1 

    The article reports that the use of serelaxin for improving acute heart failure symptoms was denied by the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA), which they explained was caused by the unclear data presented by the phase 3 RELAX-AHF trial.

  • FDA approves Eliquis to prevent DVT after hip, knee replacement surgery.  // Cardiology Today;Apr2014, Vol. 17 Issue 4, p5 

    The article reports on the approval given by the U.S. Food and Drug Administration on the Bristol-Myers Squibb and Pfizer's apixaban for the prophylaxis of deep vein thrombosis post-hip or knee replacement surgery.

  • HF risk associated with saxalgliptin under review.  // Cardiology Today;Apr2014, Vol. 17 Issue 4, p41 

    The article reports on the additional clinical trial data requested by the U.S. Food and Drug Administration (FDA) on saxagliptin due to its potential risk for heart failure (HF), which follows the publication of a study showing higher rate of HF hospitalization among patients who received...

  • Myalept approved to treat lipodystrophy.  // Cardiology Today;Apr2014, Vol. 17 Issue 4, p47 

    The article reports that metreleptin, in combination with diet, was approved by the U.S. Food and Drug Administration for use in treating complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy.

  • Northera available for neurogenic orthostatic hypotension.  // Cardiology Today;Apr2014, Vol. 17 Issue 4, p48 

    The article reports that droxidopa, indicated for patients with primary autonomic failure condition, was approved by the U.S. Food and Drug Administration for use in treating neurogenic orthostatic hypotension, which rapid approval was caused by evidence that it provided short-term relief of...

  • THE OTHER WAR ON DRUGS: FEDERAL PREEMPTION, THE FDA, AND PRESCRIPTION DRUGS AFFER WYETH V. LEVINE. PETROS III, JOSEPH F. // Notre Dame Journal of Law, Ethics & Public Policy;2011, Vol. 25 Issue 2, p637 

    The article reports on the benefits of federal preemption on the regulation of prescription drug warning labels by the U.S. Food and Drug Administration (FDA). The Wyeth vs. Levine case is presented which highlights the significance of a common direction between federal and state government. The...

  • Policy Watch. Drug shortages challenge the healthcare community, FDA, and pharmaceutical manufacturers. Wechsler, Jill // Formulary;Nov2011, Vol. 46 Issue 11, p503 

    The article reports on increased attention which the U.S. health care system, the White House and the U.S. Congress is giving in 2011 to the problem of drug shortages involving drugs that are used to treat cancer, pain and other serious medical conditions. A discussion of problems which the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics